Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals presented encouraging preclinical data for its ORIC-101 glucocorticoid receptor antagonist and ORIC-533 CD73 inhibitor at the AACR Virtual Annual Meeting II. ORIC-101 showed the ability to reverse GR-mediated resistance across various tumor models, which is critical in cancer treatment. The ongoing Phase 1b trials with enzalutamide and nab-paclitaxel aim to further assess its effectiveness. Meanwhile, ORIC-533 has demonstrated notable potency in inhibiting adenosine production, with potential benefits for immunotherapy and anti-tumor responses.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) appointed Dr. Lori Kunkel to its board of directors, enhancing its expertise in oncology and immunology. Dr. Kunkel, with over twenty-five years of experience, has played a pivotal role in the development and commercialization of various oncology therapies. CEO Jacob Chacko expressed enthusiasm for her contributions as the company advances its lead asset, ORIC-101, in clinical development. ORIC-101 is currently being tested in two Phase 1b trials, showcasing the company's commitment to overcoming therapeutic resistance in cancer.
ORIC Pharmaceuticals, a clinical-stage oncology company, will have its CEO, Jacob Chacko, present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 11:00 am ET. The company focuses on developing therapies to combat therapeutic resistance in cancer. Its lead candidate, ORIC-101, is currently undergoing Phase 1b trials in conjunction with Xtandi and Abraxane. A webcast of the presentation will be available via the investor section of their website, with a replay accessible for 90 days afterward.
ORIC Pharmaceuticals successfully completed a $138 million initial public offering, increasing its cash reserves to $204.2 million as of April 30. The funds are expected to support operations into 2023. Key developments include the first patient dosed in the ORIC-101 Phase 1b trial and promising preclinical data on the CD73 inhibitor ORIC-533. The company also strengthened its leadership team with new appointments. ORIC anticipates crucial data readouts in 2021 and plans to file for an IND for ORIC-533 in the first half of 2021.
Summary not available.
Summary not available.